

#7

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/087,464		ATTY. DOCKET NO.: S01237/70019	
				FILING DATE: March 1, 2002		CONFIRMATION NO. 8902	
				APPLICANT: Athar H. Chishti et al..			
				GROUP ART UNIT: 1636 1645		EXAMINER: Unassigned	
Sheet	1	of	3				

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		


FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			





OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	AHLBORG, Niklas et al., "Protective Immune Responses to the 42-Kilodalton (kDa) Region of <i>Plasmodium yoelii</i> Merozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa Region," <i>Infection and Immunity</i> , 2002, Pages 820-825, Vol. 70, No. 2, American Society of Microbiology	/
	C2	ANTHONY, Robert N. et al., "Sequence Analysis of the Rhop-3 Gene of <i>Plasmodium yoelii</i> ," <i>J. Eukaryot. Microbiol.</i> , 2000, Pages 319-322. Vol. 47, No. 3, Society of Protozoologists	/
	C3	BONNEFOY, S. et al., "Immunogenicity and antigenicity of a <i>Plasmodium falciparum</i> protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages," <i>Vaccine</i> , 1994, Pages 32-40, Vol. 12, No. 1, Abstract	/
	C4	BROWN, Heidi J. et al., "Primary Structure of a <i>Plasmodium falciparum</i> rhoptry antigen," <i>Molecular and Biochemistry Parasitology</i> , 1991, Pages 99-110, Vol. 49, Elsevier Science Publishers B.V.	/
	C5	CHANG, Sandra P. et al., "A Recombinant Baculovirus 42-Kilodalton C-Terminal Fragment of <i>Plasmodium falciparum</i> Merozoite Surface Protein 1 Protects <i>Aotus</i> Monkeys against Malaria," <i>Infection and Immunity</i> , 1996, Pages 253-61, Vol. 64, American Society of Microbiology	/
	C6	CLOUGH, B. et al. "Mechanism of Regulation of Malarial Invasion by Extraerythrocytic Ligands", <i>Mol. Biochem. Parasitol.</i> , 1995, Pages 19-27, Vol. 69, Elsevier Science B.V.	/
	C7	CURTIDOR, H. et al., " <i>Plasmodium falciparum</i> acid basic repeat antigen (ABRA) peptides: erythrocyte binding and biological activity," <i>Vaccine</i> , 2001, Pages 4496-4504., Vol. 19, Elsevier Science B.V.	/
	C8	DHUME, Shirish, T. et al., "Polylactosamines are not obligate receptors for invasion of <i>Plasmodium falciparum</i> malaria as shown in HEMPAS Variant II-gal ⁺ erythrocytes", <i>Glycobiology</i> , 1994, Pages 903-908, Vol. 4, No. 6, Oxford University Press	/
	C9	EGAN, Andrea F., et al., "Clinical Immunity of <i>Plasmodium falciparum</i> Malaria Is Associated with Serum Antibodies to the 19-kDa C-Terminal Fragment of the Merozoite Surface Antigen, PfMSP-1," <i>The Journal of Infectious Diseases</i> , 1996, Pages 765-769, Vol. 173, The University of Chicago	/
	C10	FRIEDMAN, Milton J. et al. "Evidence for a Malarial Parasite Interaction Site on the Major Transmembrane Protein of the Human Erythrocyte", <i>Science</i> , 1985, Pages 75-77, Vol. 228	/
	C11	GOOD, Michael F. et al., "Pathways and Strategies for Developing a Malaria Blood-Stage Vaccine," <i>Annu. Rev. Immunol.</i> , 1998, Pages 57-87, Vol. 16	/

9/15/03




FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/087,464	ATTY. DOCKET NO.: S01237/70019
		FILING DATE: March 1, 2002	CONFIRMATION NO. 8902
		APPLICANT: Athar H. Chishti et al..	
		GROUP ART UNIT: 1636 1645	EXAMINER: Unassigned
Sheet	3	of	3

	C30	SU, Shidong et al., "A Monoclonal Antibody Capable of Blocking the Binding of PF200 (MSA-1) to Human Erythrocytes and Inhibiting the Invasion of <i>Plasmodium falciparum</i> Merozoites into Human Erythrocytes," <i>The Journal of Immunology</i> , 1993, Pages 2309-2317, Vol. 151, No. 4, The American Association of Immunologists, USA	/	
	C31	URQUIZA, Mauricio et al., "Identification of <i>Plasmodium falciparum</i> MSP-1 peptides able to bind to human red blood cells," <i>Parasite Immunology</i> , 1996, Pages 515-526, Vol. 18, Blackwell Science Ltd.	/	
	C32	WEBER, James L. et al., "Primary Structure of a <i>Plasmodium falciparum</i> Malaria Antigen Located at the Merozoite Surface and within the Parasitophorous Vacuole," <i>The Journal of Biological Chemistry</i> , 1988, Pages 11421-11425, Vol. 263, No. 23, USA	/	
	C33	YANG, J.C. et al., "Seroprevalence and Specificity of Human Responses to the <i>Plasmodium falciparum</i> Rhoptry Protein Rhop-3 Determined by Using a C-Terminal Recombinant Protein," <i>Infection and Immunity</i> , 1996, Pages 3584-3591, Vol. 64, No. 9, American Society of Microbiology	/	

EXAMINER 	DATE CONSIDERED 9-15-03
--	-------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).



#10

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.: 10/087,464

ATTY. DOCKET NO.: S01237.70019

FILING DATE: March 1, 2002

CONFIRMATION NO. 8902

APPLICANT: Athar H. Chishti et al..

GROUP ART UNIT: ~~1636~~ 1645

EXAMINER: Unassigned

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C34	CRANDALL I et al., Plasmodium falciparum: sera of individuals living in a malaria-endemic region recognize peptide motifs of the human erythrocyte anion transport protein. <i>Am J Trop Med Hyg.</i> 1995 May;52(5):450-5.	/	
	C35	HOLDER AA et al., Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. <i>Nature.</i> 1985 Sep 19-25;317(6034):270-3.	/	
	C36	LAND KM et al., Anti-adhesive antibodies and peptides as potential therapeutics for Plasmodium falciparum malaria. <i>Parasitol Today</i> 1995;11(1):19-23.	/	
	C37	PAN W et al., Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. <i>Nucleic Acids Res.</i> 1999 Feb 15;27(4):1094-103.	/	
	C38	STOUTE JA et al., The current status of malaria vaccines. <i>BioDrugs</i> 1998 Aug;10(2):123-36.	/	

RECEIVED
APR 24 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

9-15-03

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).